Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 22, 2012HepatologyOpen Access

Chronic hepatitis C virus (HCV) disease burden and cost in the United States

View Full Paper
Ask AI
Bookmark
Share

Authors

HRHomie RazaviUniversity of BernAEAntoine C. ElKhouryMerck & Co., Inc., Rahway, NJ, USA (United States)EEElamin H. ElbashaMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Razavi et al. (2012) studied this question.

synapsesocial.com/papers/6a0152360acff741bf7732aehttps://doi.org/10.1002/hep.26218
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data2011 · 46 citations
  2. 2Estimates of the Cost-Effectiveness of a Single Course of Interferon-α2b in Patients with Histologically Mild Chronic Hepatitis C1997 · 317 citations
  3. 3Rising Incidence of Hepatocellular Carcinoma in the United States1999 · 2,867 citations
  4. 4Economic burden of hepatitis C‐associated diseases in the United States2011 · 79 citations
  5. 5Economic model of a birth cohort screening program for hepatitis C virus2011 · 111 citations